KALA BIO Provides CEO Update and Preliminary Third Quarter 2026 Financial Results
KALA reported approximately $7.0 million in cash, cash equivalents and short-term investments, with no debt.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
KALA BIO (NASDAQ: KALA) announced preliminary third-quarter 2026 results showing a narrower net loss of approximately $0.8 million.
The quarterly loss compared with $7.6 million in the third quarter of 2025. Net loss for the nine months ended September 30, 2026 was approximately $4.0 million, versus $27.7 million a year earlier. Cash, cash equivalents and short-term investments totaled approximately $7.0 million at September 30, with no debt.
The results are unaudited and subject to completion of financial close procedures and independent accounting review; final figures may differ. KALA expects to file its quarterly report on Form 10-Q on or about November 16, 2026.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointPreliminary quarterly net loss narrowed to approximately $0.8 million from $7.6 million in third-quarter 2025.
- Minor pointPreliminary nine-month net loss narrowed to approximately $4.0 million from $27.7 million in the same 2025 period.
- Minor pointNo debt as of September 30, 2026.
Negative
- Minor pointPreliminary, unaudited results remain subject to financial close procedures and independent accounting review; final figures may differ.
Key Figures
- Quarterly net loss
- $0.8 million
- Q3 2026; preliminary and unaudited; compared with $7.6 million in Q3 2025
- Nine-month net loss
- $4.0 million
- Nine months ended September 30, 2026; compared with $27.7 million for the same period in 2025
- Cash, cash equivalents and short-term investments
- $7.0 million
- As of September 30, 2026; no debt
- Expected Form 10-Q filing
- On or about November 16, 2026
- Quarter ended September 30, 2026
Key Terms
form 10-q regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
New York, New York--(Newsfile Corp. - November 9, 2026) - KALA BIO, Inc. (NASDAQ: KALA) today announced preliminary unaudited financial results for the quarter ended September 30, 2026.
Preliminary Third Quarter 2026 Results
- Net loss of approximately
$0.8 million for the third quarter of 2026, compared to$7.6 million for the third quarter of 2025. - Net loss of approximately
$4.0 million for the nine months ended September 30, 2026, compared to$27.7 million for the same period in 2025. - Cash, cash equivalents and short-term investments of approximately
$7.0 million as of September 30, 2026, with no debt.
"We reduced our quarterly net loss by approximately
KALA expects to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 with the SEC on or about November 16, 2026.
Preliminary Results
The results above are preliminary, unaudited and subject to completion of the Company's financial close procedures and review by its independent registered public accounting firm. Final results, to be included in the Form 10-Q, may differ.
About Kala Bio, Inc. (NASDAQ: KALA)
KALA BIO, Inc. is a clinical-stage biopharmaceutical company building a dedicated, on-premises AI infrastructure platform for the biotechnology industry. The Company's dual strategy combines a proprietary biologics pipeline—including its mesenchymal stem cell secretome (MSC-S) platform and FDA Orphan Drug- and Fast Track-designated product candidates—with a scalable AI platform-as-a-service business that deploys secure, purpose-built AI solutions directly within biotech and pharmaceutical client environments.Through its exclusive worldwide license for the Researgency AI research platform from Younet, Kala intends to serve as the dedicated AI infrastructure partner for the biotechnology industry, enabling organizations of all sizes to unlock the value of their proprietary biological data without surrendering control. Kala is advancing an agentic transformation strategy for biomedical organizations through Researgency.ai, a platform designed to enable scalable, governed deployment of AI agents across research, documentation, and operational workflows. The Company's focus on enterprise security, real-time performance, and seamless integration positions it at the forefront of innovation in the life sciences AI sector. Kala believes the future of biomedical innovation is in agentic systems.
For more information, visit www.kalarx.com and Researgency.ai.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company's preliminary unaudited financial results for the three and nine months ended September 30, 2026 and the expected timing of the filing of the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2026.
The preliminary financial results set forth in this press release are based on management's current estimates and information available as of the date of this release. They are unaudited and remain subject to the completion of the Company's financial closing procedures, final adjustments, and review by the Company's independent registered public accounting firm. The Company's actual results may differ materially from these preliminary results, and these preliminary results should not be viewed as a substitute for the full interim financial statements to be included in the Form 10-Q.
Important factors that could cause actual results or events to differ materially from those expressed or implied by these forward-looking statements include, but are not limited to: adjustments arising from the completion of the Company's financial closing procedures or the review of its interim financial statements; the identification of subsequent events or additional information prior to the filing of the Form 10-Q; delays in the completion or filing of the Form 10-Q; and other risks detailed in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2025, as may be updated in the Company's Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the Securities and Exchange Commission.
Forward-looking statements speak only as of the date of this release, and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Contact:
Avi Minkowitz
Chief Executive Officer, KALA BIO, Inc.
am@kalarx.com
www.kalarx.com | www.Researgency.ai
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/323085
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were KALA BIO's preliminary third-quarter 2026 results?
KALA BIO reported a preliminary net loss of approximately $0.8 million for the third quarter of 2026, compared with $7.6 million a year earlier. The results are unaudited and may differ from final figures.
How much cash and debt did KALA BIO report at September 30, 2026?
KALA BIO reported approximately $7.0 million in cash, cash equivalents and short-term investments as of September 30, 2026, with no debt. These figures are preliminary and unaudited.